GlassScriptPhysician profile
William H Isacoff
NPI 1891773123
$6,460.50
in general payments reported to CMS, 2019-2025
52 companies · $801 in 2025
The $801 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $999 · 2020: $938 · 2021: $957 · 2022: $1,017 · 2023: $902 · 2024: $846 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,549.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $607.97 | 2019-2025 | Opdivo, Augtyro |
| Abbvie INC. | $473.68 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $363.01 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $355.20 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $348.82 | 2019-2024 | |
| Incyte Corporation | $321.65 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| West Therapeutics Development, LLC | $287.69 | 2019-2021 | |
| Daiichi Sankyo INC. | $285.49 | 2021-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $277.35 | 2019-2025 | Enhertu, Imfinzi |
| Ipsen Biopharmaceuticals, INC | $224.00 | 2019-2025 | Tazverik |
| Amgen INC. | $215.70 | 2019-2022 | |
| Pfizer INC. | $214.30 | 2019-2023 | |
| Myriad Genetic Laboratories, INC. | $192.03 | 2022 | |
| Coherus Oncology, INC. | $175.97 | 2020-2025 | Loqtorzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.60 | 2022-2024 | Gilotrif |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Isacoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.